LY6K-AS lncRNA is a lung adenocarcinoma prognostic biomarker and regulator of mitotic progression
Ontology highlight
ABSTRACT: Purpose: Lung adenocarcinoma tumors acquire resistance to the newly-developed as well as existing therapies that restricts life quality improvements. The goal of the current study is to investigate the noncoding portion of the human transcriptome in search of actionable targets for lung adenocarcinoma treatment. Methods: The identified actionable targets (LY6K-AS lncRNA and YWHAG) were transiently downregulated in A549 cell line using either LNA-GapmeRs or siRNA. RNA was extracted from each sample and analyzed in respect to the corresponding control. Results: LY6K-AS lncRNA regulated mitotic progression in A549 cell line through the interaction with YWHAG to orchestrate the expression of several mitosis-promoting factors. Conclusions: Our study indicates that LY6K-AS silencing is a promising therapeutic option for LUAD that inhibits oncogenic mitotic progression.
ORGANISM(S): Homo sapiens
PROVIDER: GSE164419 | GEO | 2021/04/07
REPOSITORIES: GEO
ACCESS DATA